ADVERTISEMENT
Sara Hurvitz, MD, Discusses Trials on Tucatinib Therapy for HER2+ Metastatic Breast Cancer
11/28/2021
Dr Hurvitz, University of California Los Angeles Jonsson Comprehensive Cancer Center, discusses the HER2CLIMB and enrolling phase 3 HER2CLIMB-02 trials examining tucatinib's activity and safety for treatment of patients with HER2-positive metastatic breast cancer and those with stable and active brain metastases, highlighted at the virtual San Antonio Breast Cancer Symposium.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement